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Abstract   
 
Background:  Monotherapy treatment with either angiotensin-converting enzyme 
inhibitors (ACE-Is) or angiotensin type I receptor antagonists (ARBs) has been shown to 
be renoprotective in patients with Diabetes Mellitus Type II (DM II). Dual blockade of 
the renin angiotensin system (RAS) with the combination of ACE-Is and ARBs in these 
same patients might provide further benefit. 
Methods:  Exhaustive search of available medical literature using the search engines, 
Medline, CINAHL, and Science Citation Index Expanded. Articles were included which 
used multiple measurements of kidney function and patients with varying levels of 
kidney function. 
Results:  After using the exclusion criteria, a collection of articles was narrowed to 6 
studies. All articles proved a decrease in proteinuria and short term benefit in renal 
function. One article demonstrated long term harm to the kidneys. 
Conclusion:  Dual blockade of RAS reveals short term improvement of renal function 
which in the long term might have adverse effects on the kidneys. In the future longer 
term studies should be done to prove or disprove the benefits on kidney health. If dual 
therapy is beneficial then providers will be able to prescribe ACE-Is and ARBs together 
to protect the kidneys in DM II patients. 
Keywords:  Diabetic nephropathy, angiotensin II type I receptor blocker, angiotensin- 
converting enzyme inhibitor, and Diabetes Mellitus Type II. 
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Effects of Dual Blockade of the Renin­Angiotensin System Compared to Single Drug 
Treatment in Renoprotection for Patients With Diabetes Mellitus Type II and 
Diabetic Nephropathy 
 
BACKGROUND 
Diabetes Mellitus Type II (DM II) is a disease affecting many people and is 
difficult for patients to manage and live with. Diabetes has become the leading cause of 
end-stage renal disease (ESRD) in multiple countries, including the United States.1-2 
Diabetic nephropathy is characterized by persistent proteinuria or microalbuminuria, 
elevated blood pressure, persistent decline in glomerular filtration rate (GFR), and an 
increased risk for cardiovascular morbidity and mortality.1,3 Typically, proteinuria and 
hypertension are used as predictors of decreased renal function in DM II patients.1,4-5 
Proteinuria is also used as a marker of progressive renal insufficiency.6  The renin-
angiotensin system (RAS) is the key contributor to the development of renal issues in this 
population. The RAS can be targeted by two different blood pressure medications, 
angiotensin type I receptor antagonists (ARBs) and angiotensin-converting enzyme 
inhibitors (ACE-Is). Both act to decrease intraglomerular hypertension and reduce 
albumin excretion.7-8 Hypertension causes thickening of the glomerular basement 
membrane and glomerulosclerosis, leading to albuminuria.7,9 Current guidelines10 
recommend the use of either blood pressure medication as first-line agents in the 
treatment of diabetic kidney disease.10 ARBs and ACE-Is work to dilate the afferent 
vessels and efferent vessels of the kidney, respectively. ARBs work against the 
angiotensin II receptor while ACE-Is limit the conversion of angiotensin I into 
angiotensin II.1,4,8,11-16 Many researchers and providers believe that using both 
medications in combination might provide more benefit in renoprotection than a single 
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drug alone.7,17-21 Angiotensin II also promotes the synthesis of urinary transforming 
growth factor β1 (TGF-β1). When overproduction of TGF-β1 occurs, an accumulation of 
protein takes place in the renal system due to the renal tissue fibrosis, hypertrophy, and 
sclerosis.22-27 Lowering local TGF-β1 production might be possible by inhibiting the 
RAS and thus reducing angiotensin II.21 Plasma aldosterone with its fibrogenic properties 
has also been proven to have an effect on increased rate of renal function loss.28 
Preventing death, dialysis, and suffering by avoiding or slowing the progression of 
kidney disease is the goal of dual blockage of the RAS. If dual blockade of the RAS 
would show to be valuable in renoprotection then medical providers could aid their 
patients with keeping their kidneys healthy and thereby prevent suffering. 
 
METHODS 
An exhaustive literature search using the Medline, CINAHL, and Science Citation 
Index / Science Citation Index Expanded for search engines and searching the terms; 
diabetic nephropathy, angiotensin II type I receptor blocker, angiotensin-converting 
enzyme inhibitor, and Diabetes Mellitus Type II. 
Inclusion criteria for patients included those with DM II with some form of 
reduced kidney function. The intervention tested was dual blockade of RAS with 
combination ACE-Is and ARBs. No preference was given to the name brand or generic 
form of either medication. This was compared to the effects of ACE-I or ARB treatment 
alone. The desired outcome was improved kidney function. All randomized control trials 
were considered for this systematic review. Any study that was not randomized was used 
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only for background information. Studies based in any country, all time periods, and 
various measurements of kidney function were considered.  
Studies were excluded if researchers were only testing monotherapy, if they were 
not complete or concentrated on blood pressure control. Number of participants was not 
used to exclude any trials. Any studies that considered nephropathy of a different etiology 
than DMII were also excluded. 
Each article was critically appraised using the critical review form for therapy to 
measure validity and reveal bias.  Six studies were found to be valid and used for this 
systematic review. 
 
RESULTS 
The search of three different databases resulted in approximately 60 articles based 
on terms used. The most prolific database, Medline, produced 43 relevant articles with 
the keywords used and five of those studies were analyzed for this review. Seven 
applicable articles were found by CINAHL, but after exclusion criteria were applied only 
one article was determined to correspond with validity criteria. Science Citation Index / 
Science Citation Index Expanded generated one article which was a systematic review. A 
total of 13 studies were used in researching this paper. Six studies were used for their 
study and results. The remaining articles were used for background information. A 
summary of all included articles can be found in Table 1. For a synopsis of the studies 
used for the systematic review, see Table 2: Summary of findings. 
In the Krairittichai study17, dual therapy with maximal doses of both ARB 
(telmisartan 80 mg/day) and ACE-I (enalapril 40 mg/day) led to significantly reduced 
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proteinurea from baseline compared to unchanged proteinuria in ACE therapy alone. 
Urine protein/creatinine (UPCr) was used as a marker of proteinuria. Although 
researchers determined that the treatment was safe and well tolerated, GFR fell in both 
groups and potassium increased in both groups. The study included 80 patients with DM 
II, hypertension, and UPCr less than 0.5% who had been treated with the maximum 
ACE-I dosage for 3 months and were recruited from the out-patient department of 
Rajavithi Hospital in Thailand. The control group remained on ACE-I while the 
intervention group received maximal ARB in addition to ACE-I for 24 weeks.17 
The ONTARGET study18 showed greater reduction in proteinuria with dual 
therapy, but also a larger number of long term adverse effects with dual blockade of the 
RAS. Increased hypotension was a common side effect with the use of both ACE-Is and 
ARBs. The study included one of the largest number of participants and longest trial 
periods, 25 620 individuals age 55 or older with established atherosclerotic vascular 
disease or with diabetes with end-organ damage monitored for 6 years. Patients were 
randomized into 3 groups, telmisartan 80 mg /day (ARB), ramipril 10 mg/day (ACE-I), 
and a combination of both the mentioned maximal dosages. Renal function and 
proteinuria were measured using serum creatinine, GFR, and urine albumin and these 
served as surrogate renal endpoints. The primary renal outcomes used as endpoints, 
dialysis, death, and doubling of serum creatinine were more frequent with the 
combination of both drugs. The authors of this study believe that their results suggest that 
proteinuria itself should not be used as a dependable marker of improving renal function 
since proteinuria showed improvement while kidney function was decreased.18 
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Matos et al7 evaluated 20 hypertensive DM II patients over 40 years of age with 
non-nephrotic proteinuria in Rio de Janerio, Brazil. Participants were assigned to a 
random sequence of three treatments periods of 16 weeks each: perindopril 8 mg/day 
(ACE-I), irbesartan 300 mg/day (ARB), and a combination of both dosages. Multiple labs 
were measured at the end of each period to monitor renal function, including proteinuria, 
TGF-β1, plasma renin and aldosterone, blood urea nitrogen (BUN), creatinine, serum 
proteins, and urinary measurements of sodium, potassium, creatinine, and urea.  Matos 
and his fellow authors noted changes in GFR were not significant with any therapy. 
Treatment with ARBs and with dual therapy induced similar plasma renin elevation. 
Plasma aldosterone was reduced only by combination treatment. Reduction in proteinuria 
with combination therapy was not significantly different than single treatment. TGF-β1 
excretion was reduced with both ARB and combination therapy but not ACE-I therapy. 
The study showed that the combination of both hypertension medications reduced plasma 
aldosterone, proteinuria and urinary TGF-β1.7 
The CALM study19 demonstrated reduction in urinary albumin:creatinine ratio 
with combination treatment was greater than monotherapy. This study measured urinary 
albumin:creatinine ratios in patients after 12 weeks of monotherapy treatment with 
candestartan 16 mg/day (ARB) or lisinopril 20mg/day (ACE-I) followed by an additional 
12 weeks of either monotherapy or combination treatment.  The randomized, double 
blind, double dummy study took place in 37 tertiary hospitals or primary care centers in 
four countries (Australia, Denmark, Finland, and Israel). A total of 199 DM II patients 
aged 30 – 70 years with hypertension and microalbuminuria were used as participants.19 
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Sengul et al20 proved that albumin excretion rate (AER) and thus proteinuria was 
significantly more reduced with combination therapy. The study included 219 Turkish 
patients ages 40 – 65 years with DM II, hypertension and microalbuminuria who received 
lisinopril 20 mg/day (ACE-I) or telmisartan 80mg/day (ARB) for 24 weeks and were then 
randomized to either continue monotherapy or to be given a combination of both 
medications for a further 28 weeks.20 
Song et al21 illustrated no comparable change in plasma/urinary biochemical 
parameters but the 24-hour urinary protein excretion rate (UPER) was significantly 
reduced by the combination therapy. TGF-β1 was reduced in all three groups but the 
most significant change was in the combination therapy group. This study tested 21 
Korean DM II patients from 41 years old to 57 years old with hypertension and overt 
nephropathy, ranging. Each patient participated in three separate 16 week periods of 
ramipril 10 mg/day (ACE-I), candesartan 16 mg/day (ARB), and combination therapy of 
half doses of each medication. This is the only article that tested reduced dosages of the 
medications when participants were given the dual therapy. Proteinuria was shown to be 
reduced significantly even in low doses with the combination of ACE-Is and ARBs 
compared to monotherapy.21 
 
DISCUSSION 
All studies showed short term improvement in renal function with dual blockade 
of the RAS in patients with diabetic nephropathy in the short term using proteinuria as 
the surrogate marker. One study focused on long term effects such as dialysis, death, and 
doubling of serum creatinine, and thus demonstrated harm to the kidneys even though 
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there was a decrease in proteinuria. Researchers in this study referenced earlier studies 
and stated that the benefit of dual therapy might be more pronounced in patients with 
overt diabetic nephropathy or with specific proteinuric renal diseases.18  
Numerous kidney function tests were used and studies were not consistent with 
one another. Studies used various measurements of proteinuria and renal function. Only 
one study concentrated on long term renal outcomes. The ONTARGET study18 suggests 
that proteinuria alone is not an adequate marker of renal function and that major renal 
outcomes also need to be measured.18 Some of the tests used to measure renal function 
were UPCr, GFR, serum creatinine, plasma aldosterone, TGF-β1, urinary 
albumin:creatinine ratio, AER, and UPER. Matos et al7 discovered that dual blockade 
reduced plasma aldosterone and discussed that this provides further renoprotection.7 
Future studies should include more research into plasma aldosterone being a target in the 
management of diabetic nephropathy. More consistency in kidney function measurements 
would allow studies to be more easily compared and a clearer understanding of the 
effects of RAS dual blockade. 
The current research is flawed, in that all but one study,18 was done for one year 
or less thus only one study concentrated on the long term effects of dual blockade of the 
RAS. 
Some studies could not distinguish if the benefit of dual blockade on 
renoprotection could be attributed to a more effective reduction in blood pressure or to 
the additive antiproteinuric effect.19 Other studies proved that a minimal and insignificant 
blood pressure change occurred and consequently direct benefits of combination therapy 
resulted in reduced proteinuria.7 The Song et al21 study using low-dosages of dual 
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blockade also aids in distinguishing between blood pressure lowering effects and direct 
effects on the renal system.21 
Recommendations for further studies include longer studies and that studies 
include numerous and uniform tests to assess kidney function. Most researchers 
recommend close monitoring of blood pressure, renal function, and plasma potassium 
when utilizing dual blockade of the RAS. 
Many of the researchers set out to prove the benefits of dual therapy. This might 
have caused some bias when they were analyzing the data or designing their studies. 
Limitations of Study 
 The ONTARGET study18 received consulting and lecture fees and research grants 
from ARB manufacturing companies.18 This may have served to bias researchers in this 
study. The Mogensen et al19 and Matos et al7 studies also obtained funding or lecture fees 
from drug companies.7,19 
 Discrepancies among the results of the various studies could be attributed to the 
differences in ethnic profiles of the participants since the studies took place in multiple 
countries. 
 Matos et al7 explains that the antiproteinuric effect responds differently based on 
the underlying renal disease.7 This clarifies why some studies showed a greater or lesser 
improvement in proteinuria based on the type and degree of nephropathy with which 
participants had been previously diagnosed. 
 
CONCLUSION  
Dual blockade of the RAS seems like a logical treatment plan for renoprotection 
since simultaneous treatment with both ACE-Is and ARBs would obstruct the synthesis 
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and activity of angiotensin II.17 Combination therapy shows short term improvement of 
renal function but in the long term it might have adverse effects on the kidneys.18 
In the future longer term studies should be done to prove or disprove the effects 
on kidney health.  If dual therapy is beneficial, then providers will be able to prescribe 
ACE-Is and ARBs to protect the kidneys in DM II patients with hypertension and 
microalbuminuria. The DETAIL29 and VA NEPHRON-D30 studies are five year, large 
scale clinical trials comparing dual blockade of the RAS to monotherapy, but have not 
been completed.29-30 When the results are published this will present more information to 
medical providers. 
More research such as the Song et al21 study needs to be done to investigate the 
use of lower dosages in order to prevent adverse effects when testing combination 
therapy.21 Also a differentiation of renoprotective and antihypertensive effects of RAS 
blockade needs further confirmation. 
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Tables 
Table 1: Summary of Review Articles. 
Study Yr.  
published 
Patients/  
Population 
Intervention Comparison Outcome(s) Study type 
Krairittichai 
et al17 
2009;92:61
1-617. 
80 pts, DM II, 
HTN 
Dual blockade ACE alone Reduced proteinuria 
more in combo 
Randomized,  
Mann et al18 2008;372:5
47-553. 
25,620 Patients 55 
years or older with 
AVD or diabetes 
with end-organ 
damage 
Dual blockade Each drug alone Combo has greater 
reduction of 
proteinuria, but 
overall worsens 
major renal 
outcomes 
Randomized, double-
blind and single-blind 
study 
Matos et al7  2005;64:18
0-189. 
20 HTN DM II 
patients with non-
nephrotic 
proteinuria 
Dual blockade Each drug alone Combo reduces 
plasma aldosterone, 
and TGF-β1 
(proteinuria) 
Randomized, open-
label, three-phase, 
crossover study 
Mogensen 
et al19 
2000;321:1
440-1444. 
199 patients aged 
30 – 75 years 
Dual blockade Each drug alone Combo therapy 
beneficial effect on 
albuminuria 
Prospective, 
randomized, parallel 
group, double blind  
Sengul et 
al20 
2006;71:21
0-219. 
219 pts, DM II, 
age 40 – 65, HTN, 
persistent 
microalbuminuria 
Dual blockade Each drug alone Combo had greater 
reduction in BP and 
improved AER 
Prospective, 
randomized, parallel 
group, open-label, 
crossover 
Song et al21 2006;21:68
3-689. 
21 DM II with 
overt nephropathy, 
Koreans 49 +/- 8 
years 
Dual blockade 
(ramipril 
5mg/day, 
candesartan 
8mg/day) 
16 week ACE 
alone (rampiril 
10mg/day), 16 
week ARB alone 
(candesartan 
16mg/day) 
24-h UPER (urinary 
protein excretion 
rate) reduced with 
combo 
Prospective, double-
blinded randomized 
crossover trial 
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 Table 2:     Summary of Findings. 
 
 Krairittichai et al17 Mann et al18 Matos et al7 Mogensen et al19 Sengul et al20 Song et al21 
Medication 
tested for 
dual 
blockade 
telmisartan 80 mg 
(ARB) and enalapril 
40 mg (ACE-I), 
maximum doses of 
both 
telmisartan 80 mg 
(ARB) and ramipril 
10 mg (ACE-I), 
maximum doses of 
both 
irbesartan 300 
mg (ARB) and 
perindopril 8 
mg (ACE-I), 
maximum doses 
of both 
candesartan 16 
mg (ARB) and 
lisinopril 20 mg 
(ACE-I), 
maximum doses 
of both 
telmisartan 80 
mg (ARB) 
and lisinopril 
20 mg (ACE-
I), maximum 
doses of both 
candesartan 8 
mg (ARB) and 
ramipril 5 mg 
(ACE-I), half 
doses of both 
(low dose) 
Control 
medication 
enalapril 40 mg 
(ACE-I) (maximum 
dose) 
ACE-I and ARB 
alone (maximum 
doses) 
ACE-I and 
ARB alone 
(maximum 
doses) 
ACE-I and ARB 
alone (maximum 
doses) 
ACE-I and 
ARB alone 
(maximum 
doses) 
ACE-I and ARB 
alone (maximum 
doses) 
Endpoint 
measure 
UPCr, proteinuria Primary: dialysis, 
death, doubling of 
serum creatinine 
Secondary: GFR, 
proteinuria 
Proteinuria , 
TGF-β1, plasma 
aldosterone 
Proteinuria, 
urinary albumin: 
creatinine 
Albumin 
Excretion 
Rate (AER) 
24 hour urinary 
protein excretion 
rate (UPER) 
Length of 
study 
24 weeks (control 
group: ACE-I, 
intervention group: 
combination therapy) 
56 months (3 groups: 
ACE-I, ARB, 
combination therapy) 
48 weeks (three 
sessions of 16 
weeks on each 
drug) 
24 weeks (12 
weeks 
monothearpy, 12 
weeks on either 
monotherapy or 
combination 
therapy) 
52 weeks (24 
weeks on 
single drug, 
28 weeks on 
monotherapy 
or 
combination 
therapy) 
48 weeks (three 
sessions of 16 
weeks on each 
drug) 
Results of 
dual 
blockade 
Decrease in UPCr 
and proteinuria 
Decrease in 
proteinuria and GFR. 
Increase in dialysis, 
death, and doubling 
of serum creatinine. 
Decrease in 
proteinuria, 
plasma 
aldosterone, and 
TGF-β1 
Decrease in 
proteinuria 
Improved 
AER, 
decrease in 
blood 
pressure 
Decrease in 24 
hour UPER, 
proteinuria, and 
TGF-β1 
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